Corindus Vascular Robotics has announced that the first patient has been enrolled in its PRECISION GRX registry, which is a post-market study of its second-generation CorPath GRX system—a robotic-assisted percutaneous coronary intervention (PCI) device. The goal is for 1,000 patients, across 25 different sites, to be enrolled in the registry.
A press release reports that the study will gather data to evaluate patient outcomes, potential economic benefits, procedural parameters and the expanding capabilities of robotics in PCI. Additional substudies will seek to evaluate the impact of robotics on left transradial access and robotic wiring times.
Ehtisham Mahmud (UC San Diego Health, Cardiovascular Medicine and Medical Director, Sulpizio Cardiovascular Center) is the global principal investigator for the PRECISION GRX study. He says: “We have shown that robotic-assisted PCI can be used with high clinical and technical success in multiple sites with multiple operators, and the new registry is designed to evaluate the impact of the expanding capabilities of robotics. I look forward to spearheading the effort in evaluating this new technology and its value in current practice.”
The procedure on the first patient in the trial was performed by Srini Potluri at The Heart Hospital Baylor Plano—one of two Baylor hospitals participating in the registry. The hospital currently has two CorPath GRX systems installed in its catheterisation labs. Potluri states: “I am excited to participate in the PRECISION GRX registry to expand the depth of clinical research supporting robotic-assisted PCI. Our participation emphasizes our continuous commitment to advancing patient care in interventional medicine.”
